To clarify, the total financial benefit to CytoD

To clarify, the total financial benefit to CytoDyn Inc. from the settlement with Amarex can be broken down as follows:

1. **$12,000,000 payment by Amarex**:
- $10,000,000 paid on execution of the Settlement Agreement.
- $2,000,000 to be paid on or before July 2, 2025.

2. **$6,500,000 return of the Company’s cash collateral** provided as security to the surety.

3. **$14,000,000 crediting of amounts claimed by Amarex** against the Company’s outstanding balance, reducing it to zero.

However, the $14,000,000 credited against the Company’s outstanding balance is not a direct payment but rather a cancellation of the debt owed by CytoDyn to Amarex. Thus, the actual cash or cash-equivalent benefits are:

\[ \$12,000,000 + \$6,500,000 = \$18,500,000 \]

Therefore, the total direct monetary benefit is $18,500,000, while the overall financial impact, including the cancellation of the $14,000,000 debt, amounts to $32,500,000.

Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com